One place mutation, V6A, launched to the molecule drastically improved the toxicity profile and reduced VLS when compared to the WT molecule [76]. Further studies and clinical trials will likely be important to determine if this modified construct has improved basic safety and efficacy in individuals.Theoretically, IL-two has a synergistic outcome